Clene Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report; it does not provide standalone fourth-quarter results. Clene completed a reverse recapitalization on December 30, 2020 and began Nasdaq trading as CLNN. Financial statements treat Clene Nanomedicine as the accounting acquirer and include its comparative results.
Business context
Clene is a clinical-stage pharmaceutical company developing clean-surfaced nanocrystal therapeutics. Its lead candidate, CNM-Au8, is in development for multiple sclerosis (MS), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). The company also has a COVID-19 candidate, CNM-ZnAg, and earlier-stage wound-healing and oncology candidates. No drug candidate had FDA approval or generated drug-sales revenue in 2020. Small supplement sales and royalties were recorded, primarily through related-party 4Life.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0.206 million | None |
| Research and development expense | $15.204 million | $9.563 million |
| General and administrative expense | $5.151 million | $6.769 million |
| Operating loss | $20.214 million | $16.332 million |
| Net loss | $19.277 million | $16.155 million |
| Basic and diluted loss per share | $1.10 | $0.93 |
| Net cash used in operating activities | $18.929 million | $13.197 million |
| Cash at year-end | $59.275 million | $8.788 million |
2020 revenue comprised $176,000 of product revenue and $30,000 of royalty revenue. Cost of revenue was $65,000, leaving approximately $141,000 of gross profit; this small supplement business is not representative of an established drug business. Revenue was related to dietary supplements, not drug sales.
Net loss included substantial noncash, transaction-related fair-value items: a $14.615 million expense from remeasurement of preferred-stock warrant liabilities, offset in part by $14.124 million of gains from remeasurement of contingent earn-outs. The warrant liability was reclassified to equity at the business-combination closing. These items make net loss less indicative of operating cash burn.
Cash flow from investing activities was negative $0.387 million; financing activities provided $69.534 million, including preferred-stock financing, the reverse recapitalization, and a $22.2 million net PIPE investment. Year-end current assets were $62.989 million and current liabilities $11.668 million. Long-term notes payable were $1.949 million; total contractual obligations were $4.323 million, including leases. The balance sheet also included $57.959 million of contingent earn-out liabilities, which are not conventional borrowings.
Material changes versus 2019
- R&D expense increased 59% to $15.2 million as clinical programs advanced, including REPAIR-MS and REPAIR-PD and participation in the Healey ALS platform trial.
- Operating cash use rose by $5.7 million to $18.9 million. Cash increased to $59.3 million, chiefly from financing proceeds.
- General and administrative expense fell 23.9%, largely because 2019 costs included an abandoned international listing effort.
- The December 2020 reverse recapitalization converted preferred stock into common stock and brought the company public. At year-end, 59.5 million common shares were outstanding; warrants, options, and potential earn-out shares create additional dilution exposure.
Outlook, commentary, and risks
- Management expected year-end cash to fund operations for more than twelve months from issuance of the financial statements, while warning that estimates could prove wrong. The company expects continuing losses, cash use, and higher R&D spending, and may need further financing or a collaboration. The auditor’s unqualified opinion included an emphasis that additional financing or a collaboration would be required to fund future operations.
- Management anticipated VISIONARY-MS results in the first half of 2022; REPAIR-MS and REPAIR-PD data in the second half of 2021; RESCUE-ALS results in the second half of 2021; and Healey ALS platform-trial results in the first half of 2022, subject to enrollment and COVID-related restrictions. These are stated expectations, not assurances.
- Interim CNM-Au8 findings were preliminary and based on small or blinded datasets. The filing described potential clinical or biomarker improvements, but these do not establish treatment efficacy. The Phase 3 ALS study was underway; the filing does not report definitive efficacy results.
- A randomized, placebo-controlled CNM-ZnAg COVID-19 study began in Brazil in February 2021. The company’s earlier supplement case series was uncontrolled and should not be treated as evidence of clinical efficacy.
- Clinical, regulatory, manufacturing scale-up, intellectual-property, reimbursement, competition, financing, and COVID-related trial-delay risks are significant. Nanocrystal drugs have limited regulatory precedent, and long-term safety and body accumulation remain uncertainties.
- Disclosure controls were deemed ineffective because of material weaknesses in accounting expertise and oversight, formal accounting controls, journal-entry segregation, complex transaction accounting, and IT general controls. Remediation was underway and not yet complete. The financial-statement audit opinion was unqualified.
- On January 11, 2021, the SBA forgave the $0.6 million PPP loan; the company expected to recognize the gain in first-quarter 2021. A February 2021 registration statement could generate $30.7 million gross if all specified warrants are exercised; exercise is not assured. The company reported no material pending litigation and no cash dividends paid or expected in the foreseeable future.
Most important facts for investors to verify
- Current cash, operating burn, financing needs, and whether the company’s stated runway assumptions remain valid.
- Enrollment, timing, safety findings, and eventual unblinded efficacy results for the CNM-Au8 trials—especially the ALS registrational program.
- Whether preliminary biomarker and blinded MS observations translate into statistically significant, clinically meaningful benefits.
- Progress on CNM-ZnAg’s controlled COVID-19 trial and whether results support the candidate’s proposed benefit.
- Remediation and independent validation of the reported material weaknesses in internal control over financial reporting.
- Potential dilution from warrants, options, RSUs, and earn-out shares, as well as the terms and likelihood of warrant exercise.
- Manufacturing expansion, regulatory requirements, and the company’s ability to scale production while maintaining quality.